Keywords
acrometastases - hand - acral injury - finger - bone metastases
Introduction
Tumor metastases in the hand are extremely rare, with a prevalence of around 0.1% of all metastatic lesions.[1] They are more common in the lower limbs than in the upper limbs, and do not have a predominant age of onset. It is a more common pathology in men than in women.[2]
They appear more habitually in patients who are in advanced stages of cancer,[3] and lung carcinoma is the one that most frequently generates them.[4] They rarely appear as the first telltale sign of the primary pathology.[1]
They usually show up in the terminal phases of the disease, usually due to hematogenous spread, and postdiagnosis survival is usually low (average: 7 months), although it does not mean that they worsen the prognosis.[5]
The treatment will depend on the primary pathology of the patient, their life expectancy and symptoms.[6] In the present article, we describe a series of acrometastases to the hand and wrist, their therapeutic management, and review the existing literature.
Materials and Methods
The present is a retrospective review of a series of 9 cases of acrometastases only to the hand and wrist, collected in the same center between 1992 and 2020.
Data on the primary tumor, location of the metastasis in the hand, treatment and patient survival once diagnosed with acrometastases were collected from each of the cases.
In addition, a review of the literature of all the articles indexed in PubMed on acrometastases has been carried out, and, from each article, we have reviewed the primary tumor, the target organ, the demographic data, and if the acral lesion was the first sign of an unknown tumor pathology. To perform the search, we associated the keywords acrometastases and hand.
Results
The main results of our series are presented in [Table 1], in which a predominance of men (60%) with a mean age of 66 years (range: 47 to 86 years) can be observed.
Table 1
Case
|
Gender
|
Age at diagnosis (years)
|
Target
|
Primary tumor
|
Treatment
|
Survival (months)
|
1
|
Male
|
74
|
Pyramidal bone
|
Lung
|
Radiotherapy
|
8
|
2
|
Male
|
71
|
Second metacarpal
|
Lung
|
No
|
2
|
3
|
Female
|
47
|
Distal radius
|
Lung
|
Radiotherapy
|
2
|
4
|
Female
|
53
|
Distal phalanx of the ring finger
|
Breast
|
Amputation
|
3
|
5
|
Male
|
86
|
First metacarpal
|
Lung
|
No
|
7
|
6
|
Female
|
71
|
Distal phalanx of the index finger
|
Lung
|
Radiotherapy + amputation
|
2
|
7
|
Male
|
73
|
Distal phalanx of the index finger and proximal phalanx of the thumb
|
Sigmoid colon
|
Radiotherapy + amputation
|
3
|
8
|
Male
|
56
|
Distal phalanx of the index finger
|
Lung
|
Amputation + chemotherapy
|
4
|
9
|
Male
|
66
|
Distal radius
|
Kidney
|
Exeresis + ulnocarpal arthrodesis
|
43
|
In 3 of the 9 cases (case 1, 2, and 6) the metastatic lesion was the first manifestation of the disease, and in all 3 it was squamous cell carcinoma of the lung ([fig. 1a, 1b, 1c]).
Fig 1 (A) T2-weighted MRI scan showing a metastatic lesion in the distal phalanx. (B) Radiographic image of a case of lung carcinoma in anteroposterior view of the chest. (C) Image of the complete amputation of the second finger.
As for the differential diagnosis, in case number 4 there was an initial confusion in the diagnosis of the lesion, which was treated as a case of whitlow. After verifying that the antibiotic therapy was not effective, it was decided that a biopsy of the lesion should be performed, which concluded that it was a metastasis of a breast carcinoma.
Regarding treatment, for the most part, amputation with or without adjuvant radiotherapy was the most used. However, in one of the cases (number 9), the patient presented renal carcinoma with pulmonary involvement and a single metastasis in the distal radius. The osteolytic lesion was large and very painful, so the physicians decided to excise it and use the single-bone forearm technique, with the performance of an arthrodesis of the ulna and carpus.
One of the patients, whose index finger was amputated due to acrometastases secondary to carcinoma of the sigmoid colon (case number 7), had the peculiarity that a second lesion appeared 2 months later in the thumb of the contralateral hand.
The overall survival after the diagnosis was of 8.22 months (range: 2 to 43 months).
The main results of the literature review are presented in [Table 2], in which one can see that there is a male predominance, the patients have a mean age of 60 years, and the most frequent primary tumor is lung cancer (61% of the published cases), followed by kidney (11 %) and breast cancer (11%), although with a lower frequency. The acral lesion was the first sign of a previously-unknown tumor pathology in 48% of the patients.
Table 2
|
Gender (male/female)
|
Age (years)
|
Acrometastasis as first sign (cases)
|
Target
|
Primary tumor
|
Treatment
|
Survival
|
Muñoz-Mahamud et al.[8] (2017)
|
2/3
|
63
|
1/5
|
First metacarpal bone
|
Lung
|
No
|
6 months
|
Flynn et al.[9] (2008)
|
0/2
|
78
69
|
1/2
|
Second metacarpal bone;
third metacarpal bone
|
Lung;
breast
|
Radiotherapy; radiotherapy
|
Alive
|
Kumar et al. [11] (2011)
|
3/0
|
52;
60
|
2/3
|
Distal phalanx of the fifth finger; middle phalanx of the thumb
|
Squamous cell carcinoma of the esophagus;
squamous cell carcinoma of the skin
|
Radiotherapy; radiotherapy
|
|
Biyi et al.[12] (2010)
|
0/1
|
37
|
0/1
|
Middle phalanx of the left thumb
|
Breast
|
Chemotherapy
|
18 months
|
Xie[13] (2017)
|
1/0
|
45
|
0/1
|
Proximal phalanx of the left thumb
|
Lung
|
Amputation
|
|
Gilardi et al.[14] (2013)
|
1/0
|
55
|
1/1
|
Trapezium
|
Lung
|
Radiotherapy
|
Alive
|
Sahoo et al.[6] (2016)
|
1/0
|
53
|
1/1
|
Distal phalanx of the left index finger
|
Lung
|
Amputation
|
|
Liu et al.[15] (2014)
|
0/1
|
53
|
1/1
|
Second metacarpal bone
|
Lung
|
|
|
Asirvatham Gjorup et al.[16] (2017)
|
0/1
|
55
|
1/1
|
Middle phalanx of the third finger
|
Lung
|
|
2 months
|
Troncoso et al.[17] (1991)
|
|
|
1/1
|
Dstal phalanx of the finger
|
Kidney carcinoma
|
|
7 months
|
Taleb et al.[4] (2011)
|
0/1
|
46
|
1/1
|
Fourth left metacarpal bin
|
Urothelial carcinoma
|
Amputation
|
|
Lucilli et al.[18] (2010)
|
1/0
|
63
|
0/1
|
Middle phalanx of the left thumb
|
Lung
|
Amputation
|
|
Akjouj et al.[19] (2006)
|
1/0
|
57
|
1/1
|
Thumb
|
Lung
|
|
|
Bigot et al.[20] (2007)
|
1/0
|
64
|
0/1
|
Third metacarpal bone
|
Gastric carcinoma
|
|
5 years
|
Khosla et al.[21] (2012)
|
0/1
|
65
|
0/1
|
Fourth metacarpal bone
|
Vaginal carcinoma
|
|
|
Adegboyega et al.[22] (1999)
|
0/1
|
60
|
1/1
|
Middle phalanx of the third finger
|
Kidney carcinoma
|
Amputation
|
11 months
|
Rommer et al.[23] (2014)
|
1/1
|
30;
66
|
0/2
|
Distal phalanges of the fourth and fifth fingers; distal phalanx of the third finger
|
Hepatocarcinoma;
kidney carcinoma
|
Amputation;
amputation
|
-;
4 months
|
Hernández-Cortés et al.[24] (2015)
|
1/0
|
53
|
0/1
|
Distal phalanx of the fifth finger
|
Kidney carcinoma
|
|
3 months
|
Madjidi et al.[25] (2009)
|
1/0
|
55
|
1/1
|
Distal phalanx of the second finger
|
Lung
|
|
|
Borgohain et al.[26] (2012)
|
1/0
|
70
|
1/1
|
Second metacarpal bone, distal femur
|
Kidney carcinoma
|
No
|
|
Koyama and Koizumi[27] (2014)
|
1/0
|
62
|
0/1
|
Hamate
|
Lung
|
|
|
Kumar et al.[28] (2011)
|
1/0
|
55
|
0/1
|
Distal phalanges of all fingers
|
Laryngeal carcinoma
|
|
2 years
|
Gallardo-Alvarado et al.[29] (2020)
|
0/1
|
58
|
0/1
|
Right thumb
|
Cervical cancer
|
|
4 months
|
Voskuil et al.[30] (2019)
|
1/0
|
81
|
0/1
|
Scaphoid
|
Colon adenocarcinoma
|
Resection of the first row
|
1 year
|
Van Veenendaal et al.[31] (2014)
|
0/1
|
83
|
1/1
|
Proximal phalanx of the third right finger
|
Lung
|
Amputation
|
|
Miyamoto et al.[32] (2008)
|
0/1
|
72ª
|
0/1
|
Fifth metacarpal bone
|
Gastric carcinoma
|
Amputation
|
|
Ghert et al.[33] (2001)
|
0/1
|
56
|
0/1
|
Middle phalanx of the second left finger
|
Kidney carcinoma
|
Amputation
|
Alive
|
Rinonapoli et al.[34] (2012)
|
1/0
|
72
|
1/1
|
Carpus
|
Lung
|
Amputation
|
|
Tabrizi et al.[35] (2019)
|
1/0
|
60
|
1/1
|
Hamate
|
Lung
|
|
20 months
|
Salesi et al.[36] (2007)
|
|
|
0/1
|
Second left finger
|
Kidney carcinoma
|
|
|
Riter and Ghobrial[37] (2004)
|
0/1
|
53
|
0/1
|
Distal phalanx of the second right finger
|
Kidney carcinoma
|
Amputation
|
|
Lambe et al.[38] (2014)
|
1/0
|
72
|
0/1
|
Distal phalanx of the fifth finger
|
Lung
|
Radiotherapy
|
2 weeks
|
Cruz[39] (2021)
|
1/0
|
62
|
0/1
|
Third metacarpal bone
|
Chronic lymphocytic leukemia
|
|
|
Sumodhee et al.[40] (2014)
|
1/0
|
61
|
1/1
|
Middle phalanx of the fourth left finger L
|
Lung
|
Radiotherapy
|
Alive
|
Knapp and Abdul-Karim[41] (1994)
|
|
|
1/2
|
|
Lung;
dastric carcinoma
|
|
|
Lee et al.[42] (1999)
|
1/0
|
47
|
0/1
|
Middle phalanx of the thumb
|
Hepatocellular carcinoma
|
Amputation
|
5 months
|
Spiteri et al.[43] (2008)
|
1/0
|
82
|
1/1
|
Distal phalanx of the fourth right finger
|
Gastric carcinoma
|
Amputation
|
|
Ornetti et al.[44] (2012)
|
0/1
|
68
|
1/1
|
Distal phalanx of the second right finger
|
Endometrial carcinoma
|
No
|
6 months
|
Discussion
Acrometastases are uncommon in general, but more frequent in the lower extremities. In the hand, they have been described with a prevalence of around 0.1% of all bone metastases,[1] although it is probably higher due to subclinical cases and those that are not reported. The reason for this phenomenon could be the lower amount of bone marrow in the bones of the hand, as well as the lower amount of slow venous flow in these locations.[7] Afshar et al.[5] determined in their review that bone metastases distal to the elbow are more frequently caused by supradiaphragmatic tumors. In the series of the present study, 6 out of 9 cases originated from lung carcinoma. This is the primary tumor that most generates acrometastases in the hand. Although there is no proven theory, the explanation could be that the spread of these tumors is mainly hematogenous[8] and the lung has great access to arterial blood. Kidney and breast tumors are the next in terms of prevalence.[3]
It has also been seen that it affects men more than women, which could be explained by the higher frequency of lung cancer among men.[9]
In the present series, the most patients were men: 6 out of 9. In addition, except for one case, all those caused by pulmonary neoplasia occurred in men.
All the bones of the hand have been reported as metastatic targets in the literature, but the location where they most frequently settle is the distal phalanx of the dominant limb. Microtraumatisms produced by daily activities (typing, using the mobile phone...) are very common in the distal phalanx, it colud be the cause of small inflamatory reactions. The chemotherapeutic factors (prostaglandins...) produced would favor the settlement of tumor cells that arrive through the bloodstream [10] The proximal and middle phalanges, followed by the metacarpus, are next in frequency, while it is rarer that they involve the carpal bones. The most commonly-affected finger is the third,[10] which is far from the results obtained in the present review, in that there were no cases in which this finger was affected ([Fig. 2a, 2b]).
Fig 2 (A) Clinical signs of acrometastases in the distal phalanx of a second finger. (B) Radiological signs.
Regarding the diagnosis, considering the results of the literature review ([Table 2]), one can observe that in 48% of the cases it was the first symptom of the primary tumor. In the present series, in 3 out of the 9 cases, it was the first symptom of the tumor, and these 3 cases were all of lung neoplasms. The initial diagnostic orientation may be erroneous, as in one of the cases, in which a whitlow was treated, which did not improve with antibiotic therapy, and the physicians decided to perform a biopsy, which concluded that it was a metastasis of an already-known breast tumor. Therefore, a good differential diagnosis is important when facing an acral lesion of this type, since it may be confused with other entities such as: infections (case number 4), inflammatory pathologies, gout, essential cysts, and primary skin tumors.[9] Clinically, these lesions usually start with inflammation, erythema, pain, and fluctuation,[1] so they can be difficult to differentiate from other pathologies. It is important, therefore, to review the patient's clinical history, since in most cases there is a history of tumor pathology.
In the event of a suspicious lesion, apart from a good examination, imaging tests should be performed, which should include X-rays to assess bone damage. Metastatic or tumoral lesions in the hand are usually observed as lytic lesions in the bone, without periosteal reaction or joint involvement, characteristics that differentiate them from osteomyelitis[16] ([Fig. 2a], [fig. 2b]). A computed tomography (CT) scan can help expand this information. A magnetic resonance imaging (MRI) scan should be performed to assess soft-tissue involvement and adjacent neurovascular structures.
A positron-emission tomography (PET) scan can detect lesions in other locations of the body and is the test that best detects these lesions before they are symptomatic.[45] Finally, an incisional or excisional biopsy is essential to determine the anatomicopathological diagnosis.
In those patients in whom the primary pathology is unknown, coordination with the oncology unit is essential to perform the extension study and provide the best possible treatment. The overall survival of these patients with acrometastases is low, the average from diagnosis is of 7 months.[5] The appearence of acrometastases in a patient affected by a tumor indicates that said pathology is very widespread, so it is considered a bad prognostic factor.[3]
The treatment must be individualized and has two primary objectives: to reduce pain and preserve hand function, since it has not been shown in the literature that treatment improves the patient's prognosis.[5] Before performing it, it is imperative to find the primary tumor (if it is not known) and stage it, to determine the patient's survival and thus be able to offer a better treatment. The most used treatment in the literature is amputation,[5]
[7]
[9] mainly because the cases mostly involve the distal phalanges or metacarpals.[6] But when it affects bones such as the distal radius, exeresis is an option to consider, as long as the patient tolerates it. In the present series, in case 9, the technique of ulnocarpal or forearm arthrodesis of a single bone was performed in order to fulfill the two premises (pain control and preservation of function). This patient has undergone cancer treatment with chemotherapy, with good response. Two years after surgery, he required another intervention, in this case, to excise a new metastatic lesion at the level of the right elbow ([fig 3a, 3b, 3c]). After 43 months of the surgery, the patient has good pain control and no signs of local recurrence. This long survival is not uncommon, since the causal primary tumor was a renal carcinoma that was treated with nephrectomy. Jung et al.[46] have already reported a series of 8 cases of solitary metastases from primary renal tumors that were treated in the same way, and they obtained a survival of 69 months (range: 24 to 76 months).
Fig 3 (A) Radiological image of an osteolytic lesion in the distal radius. (B) Single-bone forearm technique. (C) En bloc resection of the distal radial epiphysis.
In order to control pain, the use of radiotherapy alone or associated with surgery is also very widespread,[45] although, depending on the degree of weakness of the patient, a comfort splint associated with analgesic medication may be definitive.
In conclusion, acrometastases in the hand are rare, but they must be considered in any rapidly-progressive lesion that does not respond to the usual treatments. We must be careful not to confuse these lesions with some more banal pathology, since sometimes they are the first symptom of an occult primary tumor. In cases in which the patient has already been diagnosed with a primary tumor, especially of the lung, they must be taken into consideration and treated accordingly. The type of treatment used will be more or less radical depending on the patient's condition and their life expectancy, with the sole mission of improving their quality of life. Therefore, it is important to study each case carefully and treat each patient individually.